Stephen Shrewsbury MB ChB

Dr. Shrewsbury qualified in medicine at the University of Liverpool, UK and spent 13 years working in the UK National Health Service. He joined the pharmaceutical industry 20 years ago, initially starting with Allen & Hanburys, a branch of Glaxo supporting their respiratory franchise, and launching Seretide in Europe. In 2000 Glaxo moved him to the US to lead the development of Flovent HFA and support the launch of Advair.

In 2002 he moved to Chiron Corporation to head the Seattle Clinical Development group as Senior Director, supervising the tobramycin inhalation powder project, TOBI and other inhaled programs. After moving to California in 2004, Dr. Shrewsbury joined MAP Pharmaceuticals as Vice President Clinical and Regulatory, becoming their Chief Medical Officer leading four inhaled drug programs and taking two lead candidates (in asthma and migraine) from IND to phase 3 in 18 months.

In 2008 Dr. Shrewsbury briefly joined Adamas Pharmaceuticals as Senior Vice President and CMO back in Emeryville, before joining AVI BioPharma (now Sarepta Therapeutics), as SVP Preclinical & Clinical Development and CMO, developing oligomers for neuromuscular and viral diseases. In 2011, Dr. Shrewsbury launched his firm, Shrewd Consulting LLC which has grown steadily with numerous inhaled drug clients, LifeSplice Pharma – an oligonucleotide company – launch an interactive, educational initiative, BioXpertz and support UCSF’s Clinical & Translational Science Institute T1 Catalyst Project while also writing a book, Defy Your DNA due for publication in March 2013.